GleamWall
中文EN

GOSS Gossamer Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1728117 · Fiscal year ends 12/31

Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-58.0%
TTM net income YoY-71.6%
TTM EPS YoY-221.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-361.9%
Net margin-344.8%
FCF margin-383.7%
EBITDA margin-361.1%

Returns

ROE-783.4%
ROA-45.2%
ROIC (approx.)—
Asset turnover0.13x

Leverage & solvency

Liabilities / assets119.1%
Debt / equity—
Current ratio4.40x
Interest coverage-13.28x

Cash quality & payout

Operating cash flow / net income1.11x
Accruals ratio5.1%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$48.47M$114.70M
R&D expense$174.09M$138.49M
SG&A expense$37.63M$36.13M
Operating income-$170.73M-$59.92M
Interest expense$10.99M$11.52M
Pretax income-$170.46M-$55.63M
Income tax-$88,000$893,000
Net income-$170.37M-$56.53M
EBITDA-$170.70M-$59.09M
EPS (basic)-0.75-0.25
EPS (diluted)-0.75-0.25
Weighted avg. shares (diluted)228.52M226.23M
Balance sheet
Cash & equivalents$37.73M$46.07M
Short-term investments$99.20M$248.44M
Receivables$12.23M$5.34M
Current assets$167.64M$309.89M
PP&E, net$64,000$10,000
Total assets$172.25M$315.29M
Current liabilities$63.44M$45.01M
Short-term debt—$0
Long-term debt—$0
Total debt—$0
Total liabilities$295.01M$285.80M
Shareholders' equity-$122.76M$29.49M
Net debt—-$46.07M
Shares outstanding2.92M226.60M
Cash flow statement
Operating cash flow-$171.27M-$3.47M
Capital expenditure$79,000$0
Free cash flow-$171.34M-$3.47M
Investing cash flow$156.36M$29.02M
Financing cash flow$6.42M-$11.49M
Depreciation & amortization$24,000$833,000
Stock-based compensation$10.55M$20.62M

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.